Lithobid: Essential Guide

2024.05.17.

Characteristic	Details
Generic Name	Lithium Carbonate
Brand Name	Lithobid
Dosage Form	Tablet, Extended Release
Strength	300 mg
Indication	Bipolar Disorder
Administration Route	Oral
Storage	Room Temperature
Visit Lithobid Site

Pharmacokinetics of Lithobid 300 mg

Lithobid 300 mg is primarily absorbed through the gastrointestinal tract. It achieves peak plasma concentrations within 1-3 hours post-administration. The pharmacokinetic profile is nonlinear due to its variable absorption rate. The half-life ranges from 18 to 36 hours, dependent on renal function and dosing frequency. Distribution occurs throughout the body, crossing the blood-brain barrier. Elimination relies on renal excretion, necessitating adjustments for patients with compromised kidney function.

Metabolism does not affect Lithobid 300 mg. It is not bound to plasma proteins. This property makes drug interactions minimal compared to highly protein-bound medications. Therapeutic levels should be closely monitored to avoid toxicity. Serum concentrations should range between 0.6 to 1.2 mEq/L. Deviations from this range necessitate dosage adjustments or cessation.

Correct Use of Lithobid 300 mg

Prescribing Lithobid 300 mg requires careful consideration of patient history. Administer the drug orally, with or without food. Encourage patients to consume a consistent amount of salt and maintain adequate hydration. Sudden changes in diet can affect drug levels.

Monitoring of serum lithium levels should occur regularly, particularly during the initiation phase. Adjust dosages based on clinical response and side effect profile. Advise patients to report any signs of lithium toxicity, such as tremors or gastrointestinal disturbances. Emphasize adherence to prescribed dosing schedules to maintain steady-state concentrations.

Lithobid 300 mg Contraindications

Lithobid 300 mg is contraindicated in patients with significant renal impairment. Patients with cardiovascular disease should use caution due to sodium content and fluid balance requirements. Avoid in individuals with hypersensitivity to lithium compounds. Concomitant use with diuretics requires careful monitoring to prevent toxicity.

Thyroid function alterations may occur; periodic thyroid tests are essential. Caution is advised for patients with a history of thyroid disorders. Pregnancy and breastfeeding necessitate a risk-benefit analysis due to potential neonatal toxicity.

Lithobid 300 mg Storage Conditions

Store Lithobid 300 mg tablets at room temperature. Avoid exposure to excessive heat and moisture. Secure the medication in a location inaccessible to children. Check expiration dates regularly, and discard expired tablets properly.

Maintain original packaging to protect from light and humidity. Proper storage ensures the medication’s efficacy and reduces risk of accidental ingestion or misuse.

Toxicity of Lithobid 300 mg

Lithobid 300 mg has a narrow therapeutic index, increasing the risk of toxicity. Symptoms include nausea, diarrhea, tremors, and confusion. Severe cases may lead to seizures or coma. Immediate medical intervention is crucial upon suspicion of overdose.

Monitor renal function routinely, as impaired kidneys can lead to accumulation and heightened risk. Prolonged toxicity may result in irreversible neurological damage. Patient education on recognizing early signs is vital for prevention.

Accessing Lithobid 300 mg Responsibly

Acquiring Lithobid 300 mg without a prescription poses significant health risks. Self-medication bypasses essential monitoring for side effects and toxicity. Professional guidance ensures appropriate usage and adjustments.

Legitimate prescriptions provide a framework for safe administration. This includes regular blood tests and dosage modifications based on therapeutic response. Avoid online purchases from unverified sources to prevent counterfeit medication risks.

Parameter	Value
Half-Life	18-36 hours
Peak Concentration	1-3 hours
Therapeutic Range	0.6-1.2 mEq/L